Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$620.97 +1.0%	$597.89	$352.77 ▼ $678.21	$37.92B	0.6	306,639 shs	241,273 shs
GSK GSK	$38.09 +1.8%	$37.53	$31.72 ▼ $45.93	$78.59B	0.56	4.70 million shs	5.76 million shs
SNY Sanofi	$52.76 +0.8%	$54.51	$45.80 ▼ $60.12	$133.29B	0.57	2.35 million shs	2.01 million shs
TAK Takeda Pharmaceutical	$15.17 +0.9%	$14.75	$12.58 ▼ $15.37	$46.84B	0.39	1.87 million shs	1.53 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	+1.01%	+4.24%	+5.40%	-4.19%	+66.57%
GSK GSK	+1.79%	+4.30%	-1.68%	+8.47%	-7.35%
SNY Sanofi	+0.84%	+3.59%	-5.48%	-0.40%	+7.39%
TAK Takeda Pharmaceutical	+0.93%	+1.54%	+0.76%	+13.34%	+16.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.1684 of 5 stars	3.5	2.0	0.0	3.5	1.7	1.9
GSK GSK	1.282 of 5 stars	1.3	3.0	2.5	1.9	0.0	1.3
SNY Sanofi	3.722 of 5 stars	2.5	4.0	2.5	3.4	0.0	3.1
TAK Takeda Pharmaceutical	2.5896 of 5 stars	0.0	4.0	1.7	2.7	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	2.91	Moderate Buy	$699.28	12.61% Upside
GSK GSK	2.55	Moderate Buy	$40.58	6.55% Upside
SNY Sanofi	3.00	Buy	$63.33	20.04% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest TAK, SNY, GSK, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$681.00 ➝ $796.00
4/15/2025	GSK GSK	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$35.25
4/15/2025	SNY Sanofi	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
4/11/2025	ARGX argenx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00 ➝ $715.00
4/8/2025	ARGX argenx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00 ➝ $720.00
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
3/21/2025	SNY Sanofi	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
3/17/2025	ARGX argenx	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/12/2025	ARGX argenx	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold
3/10/2025	ARGX argenx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$775.00 ➝ $1,100.00
3/4/2025	ARGX argenx	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$650.00 ➝ $680.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.19B	17.31	N/A	N/A	$69.22 per share	8.97
GSK GSK	$31.38B	2.50	$6.03 per share	6.32	$8.07 per share	4.72
SNY Sanofi	$44.29B	3.01	$5.19 per share	10.16	$33.20 per share	1.59
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.55 per share	4.27	$15.39 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$12.59	N/A	57.23	N/A	-2.11%	-1.45%	-1.29%	5/8/2025 (Estimated)
GSK GSK	$3.29B	$1.59	23.96	8.19	1.12	8.13%	48.59%	11.11%	4/30/2025 (Estimated)
SNY Sanofi	$6.02B	$2.80	21.19	11.11	1.01	12.77%	25.61%	14.72%	N/A
TAK Takeda Pharmaceutical	$994.06M	$0.40	37.93	9.19	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)

Latest TAK, SNY, GSK, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ARGX argenx	$0.98	N/A	N/A	N/A	$748.34 million	N/A
4/30/2025	Q1 2025	GSK GSK	$1.06	N/A	N/A	N/A	$7.52 billion	N/A
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion
2/27/2025	Q4 2024	ARGX argenx	$0.98	$1.58	+$0.60	$11.79	$678.52 million	$761.22 million
2/5/2025	Q4 2024	GSK GSK	$0.44	$0.59	+$0.15	$0.26	$7.75 billion	N/A
1/30/2025	Q4 2024	SNY Sanofi	$0.70	$0.70	N/A	$0.29	$10.57 billion	N/A
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.60	4.20%	-17.33%	100.63%	N/A
SNY Sanofi	$1.60	3.03%	+1.84%	57.14%	N/A
TAK Takeda Pharmaceutical	$0.53	3.49%	-8.36%	132.50%	N/A

Latest TAK, SNY, GSK, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025
2/5/2025	GSK GSK	quarterly	$0.3932	4.2%	2/21/2025	2/21/2025	4/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
GSK GSK	1.12	0.78	0.52
SNY Sanofi	0.15	1.46	1.14
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
GSK GSK	15.74%
SNY Sanofi	14.04%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
GSK GSK	10.00%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	61.06 million	59.29 million	Optionable
GSK GSK	90,100	2.06 billion	1.87 billion	Optionable
SNY Sanofi	91,600	2.53 billion	2.51 billion	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

ARGX, SNY, GSK, and TAK Headlines

Recent News About These Companies

JPMorgan Chase & Co. Has $1.11 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 29 at 3:06 AM | marketbeat.com

‘Made in India’ dengue vaccine likely to be launched next year. Here’s what we know

April 28 at 1:04 PM | firstpost.com

Syon Capital LLC Has $486,000 Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 27 at 5:58 AM | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Mariner LLC

April 27 at 4:03 AM | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by First Trust Advisors LP

April 26 at 4:56 AM | marketbeat.com

XTX Topco Ltd Trims Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 26 at 4:15 AM | marketbeat.com

Teduglutide improves stool outcomes in children with short bowel syndrome over 96 weeks

April 25, 2025 | healio.com

Japanese pharmaceutical firm Takeda’s profits hit by €37m impairment charge

April 24, 2025 | msn.com

Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Up 7.02%

April 23, 2025 | aaii.com

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

April 23, 2025 | kansascity.com

5 minutes with… Dr Tami Nussbaum, Takeda

April 23, 2025 | emjreviews.com

Capital Research Global Investors Buys 25,309 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 23, 2025 | marketbeat.com

Sterling Capital Management LLC Cuts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 23, 2025 | marketbeat.com

How Takeda's CEO transformed the company into a global pharma powerhouse

April 23, 2025 | msn.com

Japan drug companies offer rare haven amid Trump market jitters

April 22, 2025 | asia.nikkei.com

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

April 21, 2025 | zacks.com

Forum Financial Management LP Acquires 65,399 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 21, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Trimmed by Cerity Partners LLC

April 21, 2025 | marketbeat.com

Envestnet Asset Management Inc. Sells 460,843 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 19, 2025 | marketbeat.com

Towards gene-targeting drugs capable of targeting brain diseases

April 17, 2025 | sciencedaily.com

Cholesterol-modified oligonucleotides show promise for treating brain diseases

April 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
By Sam Quirke | April 3, 2025
View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?

ARGX, SNY, GSK, and TAK Company Descriptions

argenx NASDAQ:ARGX

$620.97 +6.21 (+1.01%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$620.07 -0.90 (-0.14%)

As of 04:33 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

GSK NYSE:GSK

$38.09 +0.66 (+1.76%)

Closing price 04/28/2025 03:59 PM Eastern

Extended Trading

$38.09 +0.00 (+0.00%)

As of 04:21 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi NASDAQ:SNY

$52.76 +0.44 (+0.84%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$53.01 +0.25 (+0.47%)

As of 04:04 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$15.17 +0.14 (+0.93%)

Closing price 04/28/2025 03:59 PM Eastern

Extended Trading

$14.98 -0.19 (-1.25%)

As of 04/28/2025 07:32 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time